Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to endogenous endophthalmitis.
Choroidal neovascularization is a major cause of visual loss in age-related macular degeneration. It is also a potential vision-threatening complication of pathologic myopia, uveitis, traumatic choroidal rupture and, rarely, endophthalmitis. Here, we report a 36-year-old woman with acute lymphocytic leukemia and fungal pneumonia after chemotherapy who developed endogenous endophthalmitis in both eyes. The infection was controlled by systemic antibiotic and antifungal agents. Unfortunately, choroidal neovascularization developed in the right macula 1 month later. One dose of intravitreal injection of ranibizumab (0.5 mg/0.05 mL) was given, and the macular exudates resolved rapidly. There was no recurrence or complications during the 10-month follow-up.
Sheu
Shwu-Jiuan
SJ
Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. sjsheu@vghks.gov.tw
D000287:Administration, Topical; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D009877:Endophthalmitis / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069579:Ranibizumab
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab